12.2 Hypertensive Disorders and High-Risk Pregnancy Complications

12.2 Hypertensive Disorders and High-Risk Pregnancy Complications

Hypertensive disorders and third-trimester hemorrhagic emergencies constitute the leading causes of maternal and perinatal morbidity and mortality worldwide. Rapid clinical recognition, rigorous pharmacological titration, and prompt emergency nursing interventions are required to stabilize maternal hemodynamics and preserve fetal viability.

---

The Spectrum of Hypertensive Disorders of Pregnancy

Hypertensive disorders complicate approximately 10% of all pregnancies and are classified into four distinct diagnostic categories:

1. Chronic Hypertension

Hypertension (systolic blood pressure [SBP] >= 140 mmHg or diastolic blood pressure [DBP] >= 90 mmHg) that is present prior to conception or diagnosed before 20 weeks of gestation. If diagnosed during pregnancy, hypertension that persists beyond 12 weeks postpartum is also categorized as chronic hypertension.

2. Gestational Hypertension

New-onset blood pressure elevation (SBP >= 140 mmHg or DBP >= 90 mmHg on two occasions at least 4 hours apart) developing after 20 weeks of gestation in a woman with previously normal blood pressure, without proteinuria and without severe systemic organ features. Blood pressure returns to normal baseline within 12 weeks postpartum. If gestational hypertension is accompanied by proteinuria or severe end-organ damage, the diagnosis shifts to preeclampsia.

3. Preeclampsia: Diagnostic Criteria & Pathophysiology

Preeclampsia is a multi-system, vasospastic syndrome characterized by abnormal placental vascular remodeling. Early in gestation, maternal spiral arteries fail to undergo normal trophoblast-mediated endovascular trophoblast invasion, remaining narrow, tortuous, and hyper-reactive. The resulting placental hypoperfusion triggers the continuous release of anti-angiogenic factors (e.g., soluble fms-like tyrosine kinase-1 [sFlt-1]) into the maternal circulation, inducing widespread maternal vascular endothelial cell dysfunction, generalized vasospasm, and increased capillary permeability across all organ systems.

Diagnostic Criteria for Preeclampsia without Severe Features:

• Systolic BP >= 140 mmHg or diastolic BP >= 90 mmHg on two occasions at least 4 hours apart after 20 weeks of gestation in a previously normotensive woman, AND
• Proteinuria: Documented as >= 300 mg per 24-hour urine collection, a spot urine protein-to-creatinine ratio >= 0.3 mg/mg, or persistent dipstick reading of 1+ (used only if quantitative methods are unavailable).

Diagnostic Criteria for Preeclampsia with Severe Features:

Diagnosed when blood pressure elevation is severe, OR in the presence of any secondary end-organ dysfunction (even if proteinuria is completely absent):

1. Severe Blood Pressure Elevation: SBP >= 160 mmHg or DBP >= 110 mmHg on two occasions at least 4 hours apart while the patient is on bed rest (or confirmed within minutes to facilitate rapid antihypertensive initiation).
2. Thrombocytopenia: Platelet count < 100,000 cells/mcL.
3. Impaired Renal Function: Serum creatinine > 1.1 mg/dL (or a doubling of the baseline serum creatinine in the absence of pre-existing renal disease).
4. Impaired Hepatic Function: Serum transaminases (AST, ALT) elevated to twice the upper limit of normal, or persistent, severe epigastric or right upper quadrant pain unresponsive to analgesics and not explained by alternative diagnoses.
5. Pulmonary Edema: Fluid extravasation into alveolar spaces presenting with dyspnea, tachypnea, basilar crackles, and hypoxemia.
6. New-Onset Neurological Symptoms: Persistent, severe, throbbing headache unresponsive to acetaminophen, photopsia, scotomata (visual field dark spots), blurred vision, hyperreflexia, clonus, or altered mental status.

4. Eclampsia

The onset of new generalized tonic-clonic seizures or unexplained coma in a woman with preeclampsia, not attributable to other central nervous system pathology (e.g., epilepsy, intracranial hemorrhage, meningitis). Eclampsia can occur antepartum (50%), intrapartum (25%), or postpartum (25%, typically within 48 hours of delivery).

Emergency Nursing Management of an Eclamptic Seizure:

1. Maintain Airway and Patient Safety: Immediately turn the patient onto her left side to prevent aspiration of vomitus and oral secretions and to displace the uterus off the vena cava. Pad the side rails and lower the bed. NEVER attempt to force a tongue blade or airway into the patient's mouth during an active seizure; do not restrain muscular movements.
2. Oxygenation: Following seizure cessation, suction the oropharynx as needed and apply high-flow 100% oxygen via a non-rebreather face mask at 10 to 12 L/min.
3. Control Seizures: Administer an immediate intravenous bolus of Magnesium Sulfate (if an infusion is not running, administer 4 to 6 g IV over 15 to 20 minutes; if already running, administer an additional 2 g IV bolus over 3 to 5 minutes).
4. Surveillance & Stabilization: Obtain maternal vital signs, assess for uterine hypertonus or abruption, and evaluate fetal heart rate pattern. Delivery is the definitive cure for preeclampsia/eclampsia, but delivery must be deferred until maternal hemodynamic stabilization, oxygenation, and seizure control are achieved.

5. HELLP Syndrome

HELLP syndrome is a life-threatening, progressive variant of preeclampsia characterized by microangiopathic hemolytic anemia, hepatic necrosis, and consumptive thrombocytopenia. It occurs in 10% to 20% of women with severe preeclampsia, though up to 15% of patients present with normal or only mildly elevated blood pressure.

 H ──► HEMOLYSIS: Microangiopathic hemolytic anemia; RBCs fragmented passing through
                   damaged, fibrin-coated vessels -> Schistocytes on peripheral blood smear,
                   elevated indirect bilirubin (≥ 1.2 mg/dL), elevated LDH (> 600 U/L).

EL ──► ELEVATED LIVER ENZYMES: Hepatic sinusoidal fibrin deposition & ischemic necrosis ->
                               AST and ALT elevated ≥ twice the upper limit of normal,
                               elevated Lactate Dehydrogenase (LDH > 600 U/L).

LP ──► LOW PLATELETS: Platelet aggregation and consumption at sites of endothelial damage ->
                      Thrombocytopenia with platelet count < 100,000 cells/mcL.

• Clinical Presentation: The pathognomonic symptom is severe, persistent epigastric or right upper quadrant (RUQ) abdominal pain (present in 90% of cases), caused by hepatic sinusoidal obstruction, intrahepatic microvascular congestion, and stretching of Glisson's capsule. Patients frequently complain of malaise, nausea, vomiting, flu-like symptoms, and jaundice.
• Life-Threatening Complications: Subcapsular liver hematoma and fatal hepatic rupture (heralded by sudden, catastrophic RUQ pain radiating to the shoulder, accompanied by profound hypovolemic shock), disseminated intravascular coagulation (DIC), placental abruption, and acute renal failure.
• Nursing Priorities: Insert two large-bore IV lines, type and crossmatch packed red blood cells and platelets, initiate intravenous magnesium sulfate seizure prophylaxis, avoid aggressive abdominal palpation (which can rupture a subcapsular hematoma), and prepare for emergent delivery.

---

Diagnostic Matrix of Hypertensive Disorders in Pregnancy

---

Magnesium Sulfate Infusion & Toxicity Monitoring

Intravenous Magnesium Sulfate ($MgSO_4$) is the globally accepted, evidence-based gold standard drug for the prevention and treatment of eclamptic convulsions. It is not administered as a primary antihypertensive agent; its primary clinical objective is central neuroprotection and seizure prophylaxis.

1. Mechanism of Action & Hemodynamics

Magnesium sulfate acts as a central nervous system depressant and competitive calcium antagonist. It blocks peripheral neuromuscular transmission by decreasing acetylcholine release from motor nerve terminals and reduces calcium influx at post-synaptic motor endplates, raising the seizure threshold. It also produces modest systemic and cerebral arteriolar vasodilation, relieving cerebral vasospasm.

2. Administration & Infusion Protocol

• IV Loading Dose: 4 to 6 grams of magnesium sulfate diluted in 100 mL of 0.9% normal saline or Lactated Ringer's, administered via an automated infusion pump over 15 to 20 minutes.
• Continuous IV Maintenance Dose: 1 to 2 grams per hour continuously infused via a secondary line "piggybacked" into the primary IV infusion at the closest proximal port.
• Therapeutic Serum Window: 4.0 to 7.0 mEq/L (or 4.8 to 8.4 mg/dL / 2.0 to 3.5 mmol/L). At therapeutic levels, maternal deep tendon reflexes remain intact, seizures are prevented, and consciousness is clear.

3. Hourly Nursing Surveillance Protocol

Because magnesium sulfate is excreted entirely by the maternal kidneys, any decline in renal perfusion triggers rapid systemic drug accumulation and life-threatening toxicity. The registered nurse must perform and document clinical evaluations every 60 minutes:

                      [ Magnesium Sulfate Hourly Nursing Triad ]
                                         │
         ┌───────────────────────────────┼───────────────────────────────┐
         ▼                               ▼                               ▼
[ Deep Tendon Reflexes ]       [ Respiratory Rate ]            [ Urine Output ]
- Test Patellar Reflex (2+)     - Count full 60 seconds         - Foley catheter with urometer
- Normal: 2+ brisk reflex       - Must be ≥ 12 breaths/min      - Must be ≥ 30 mL/hour
- Loss of DTRs = First sign     - < 12 = Respiratory arrest    - Oliguria -> Rapid accumulation
  of toxicity (8-10 mEq/L)        risk (10-12 mEq/L)              of lethal magnesium levels

1. Deep Tendon Reflexes (DTRs): Assess the patellar (knee-jerk) or biceps reflex. Normal reactivity is graded 2+. The gradual weakening or complete loss of DTRs (0 grade) is the earliest, most reliable clinical indicator of magnesium toxicity, typically manifesting at serum concentrations of 8 to 10 mEq/L.
2. Respiratory Rate & Depth: Auscultate and count the respiratory rate for a full 60 seconds. The respiratory rate must be >= 12 breaths per minute. Severe respiratory depression and bradypnea develop at 10 to 12 mEq/L, progressing to complete respiratory arrest at levels > 12 to 15 mEq/L.
3. Hourly Urinary Output: An indwelling urinary catheter (Foley) equipped with an urometer must be in place. Urine output must remain >= 30 mL/hour (or >= 100 mL over 4 consecutive hours). If urinary output drops below 30 mL/hr, magnesium clearance is severely impaired, mandating immediate notification of the obstetrician and possible rate reduction or serum drug level measurement.
4. Neuromuscular & Sensorium Status: Continuous assessment for excessive somnolence, slurred speech, generalized flaccid muscular paralysis, or blurred vision. Cardiac conduction disturbances (widened PR interval, prolonged QRS, complete heart block) and asystole/cardiac arrest occur at lethal concentrations > 15 to 20 mEq/L.

4. Acute Magnesium Toxicity Emergency Protocol

If the patient exhibits absent deep tendon reflexes, a respiratory rate < 12 breaths/min, oxygen desaturation, severe hypotension, or acute oliguria, execute the following actions immediately:

1. STOP the Magnesium Sulfate Infusion Immediately! Turn off the secondary infusion pump clamp.
2. Airway & Oxygenation: Maintain open airway and administer high-flow 100% oxygen at 10 to 12 L/min via a non-rebreather face mask.
3. Notify the Provider: Call the rapid response / obstetric emergency team immediately.
4. Administer the Specific Antidote:
   • Calcium Gluconate 10% Solution: Administer 1 gram (10 mL of a 10% solution) IV push slowly over 3 to 5 minutes.
   • Mechanism: Calcium acts as a physiological antagonist, competitively displacing magnesium at motor endplate receptors, instantly reversing neuromuscular blockade, restoring diaphragmatic contractions, and stabilizing cardiac membranes.
   • Safety Note: Rapid IV push of calcium gluconate can provoke severe maternal bradycardia and dysrhythmias; administer slowly while monitoring cardiac rate.

5. Antihypertensive Pharmacotherapy for Severe Hypertension

Antihypertensive medications are indicated for acute SBP >= 160 mmHg or DBP >= 110 mmHg to prevent maternal cerebrovascular hemorrhage and encephalopathy (target blood pressure: 140–150 / 90–100 mmHg; avoiding precipitous drops that compromise placental perfusion):

• IV Labetalol: Combined alpha- and beta-adrenergic blocker. Initial dose 20 mg IV bolus over 2 minutes. If blood pressure remains elevated after 10 minutes, administer 40 mg, then 80 mg every 10 minutes (maximum cumulative dose: 300 mg). Contraindications: Asthma, congestive heart failure, severe sinus bradycardia (HR < 60 bpm).
• IV Hydralazine: Direct arteriolar vasodilator. Initial dose 5 to 10 mg IV over 2 minutes. Repeat with 10 mg IV after 20 minutes if needed. Can cause reflex tachycardia and maternal headaches.
• Oral Immediate-Release Nifedipine: Calcium channel blocker. Initial dose 10 to 20 mg orally (swallowed, never administered sublingually due to risks of catastrophic, uncontrolled hypotension); repeat in 20 minutes if necessary.

Third-Trimester Bleeding: Placenta Previa vs. Abruptio Placentae

Obstetric hemorrhage in the second half of pregnancy is an acute emergency. Clinical differentiation between placenta previa and abruptio placentae dictates immediate life-saving nursing interventions.

                      [ Third-Trimester Hemorrhage Differential ]
                                          │
         ┌────────────────────────────────┴────────────────────────────────┐
         ▼                                                                 ▼
[ Placenta Previa ]                                             [ Abruptio Placentae ]
- Abnormal implantation over cervical os                       - Premature placental detachment from decidua
- PAINLESS, bright red bleeding                                 - PAINFUL, dark red or concealed bleeding
- Uterus is SOFT, relaxed, non-tender                           - Uterus is RIGID, board-like, hypertonic
- Normal resting uterine tone                                   - High resting uterine tone (> 20-25 mmHg)
- FHR usually normal / reassuring                               - Fetal distress, late decels, severe bradycardia
- Digital pelvic exam STRICTLY FORBIDDEN!                       - High risk of Hypovolemic Shock and DIC!

1. Placenta Previa

• Pathophysiology: The placenta implants abnormally in the lower uterine segment, encroaching upon or entirely covering the internal cervical os. As the lower uterine segment thins and elongates in the third trimester, placental attachment fibers tear, opening venous sinuses.
  • Complete Previa: Internal os is completely covered by placental tissue.
  • Partial Previa: Internal os is partially occluded.
  • Marginal / Low-Lying: Edge of placenta lies within 2 cm of the internal os.
• Clinical Presentation: Sudden onset of painless, bright red vaginal bleeding occurring during the second or third trimester. The maternal abdomen is soft, relaxed, non-tender, with completely normal uterine resting tone. Fetal heart rate and heart rate variability typically remain normal and reassuring unless excessive maternal blood loss induces profound maternal hypovolemic shock.
• Risk Factors: Multiparity, advanced maternal age (> 35 years), previous Cesarean delivery, prior uterine curettage, smoking, and multiple gestation.
• MANDATORY CLINICAL SAFETY DIRECTIVE:
  • NEVER perform a digital vaginal examination (PV exam) or insert anything into the vagina until placental location is definitively verified by ultrasound!
  • Inserting a gloved finger through the cervical os can tear the low-lying placental cotyledons, triggering catastrophic, exsanguinating hemorrhage within seconds.
• Management: Diagnosis confirmed by transabdominal or transvaginal ultrasound. Complete and partial placenta previa mandate delivery via Cesarean section; vaginal birth is unsafe due to hemorrhage risk.

2. Abruptio Placentae (Placental Abruption)

• Pathophysiology: The premature partial or complete detachment of a normally implanted placenta from the decidua basalis after 20 weeks of gestation and prior to the delivery of the fetus. Rupture of maternal arterioles in the decidua basalis forms a retroplacental hematoma that shears the placenta off the uterine wall, severing fetal gas exchange.
• Clinical Classification:
  • Concealed Hemorrhage (20%): The retroplacental hematoma remains trapped behind the placental margins. Blood does not escape through the cervix; there is no visible external vaginal bleeding, yet the patient experiences excruciating pain and rapid hemodynamic collapse.
  • Revealed / Overt Hemorrhage (80%): The blood dissects between the fetal membranes and the uterine wall, escaping through the cervix as dark red vaginal bleeding.
• Clinical Presentation: Sudden onset of severe, sharp, unremitting localized abdominal, uterine, or back pain, accompanied by dark red vaginal bleeding (or no bleeding if concealed). Palpation reveals a firm, rigid, "board-like" abdomen and intense uterine tenderness. Uterine resting tone is elevated (> 20 to 25 mmHg on intrauterine pressure catheter), demonstrating frequent, high-frequency, low-amplitude hypertonic contractions. Fetal heart rate monitoring demonstrates severe fetal distress (recurrent late decelerations, loss of variability, profound bradycardia, or fetal demise).
• Risk Factors: Maternal hypertension and preeclampsia (the single greatest risk factor, accounting for > 50% of severe abruptions), blunt abdominal trauma (motor vehicle accidents, domestic violence), cocaine or methamphetamine use (inducing sudden severe vasospasm), cigarette smoking, premature rupture of membranes, and sudden uterine decompression (after delivery of a first twin or amniotic fluid rupture in polyhydramnios).
• Life-Threatening Complication: Disseminated Intravascular Coagulation (DIC):
  • Massive retroplacental tissue damage releases large quantities of tissue thromboplastin into the maternal venous circulation, initiating the extrinsic coagulation cascade.
  • Widespread microvascular thrombosis consumes circulating fibrinogen, prothrombin, and platelets, precipitating a state of severe secondary consumptive coagulopathy (DIC).
  • Clinical Indicators of DIC: Spontaneous oozing or bleeding from IV puncture sites, venipuncture hematomas, petechiae, ecchymoses, hematuria, epistaxis, bleeding gums; laboratory findings reveal profoundly low fibrinogen (< 150 mg/dL), markedly elevated D-dimer / fibrin split products, prolonged PT/INR and aPTT, and severe thrombocytopenia.
• Emergency Nursing Interventions for Abruptio Placentae:
  1. Establish two large-bore (16- or 18-gauge) peripheral IV lines immediately.
  2. Administer rapid crystalloid volume resuscitation (0.9% normal saline or Lactated Ringer's) to combat hypovolemic shock.
  3. Draw emergency laboratory tests: Type and crossmatch 4 units of packed red blood cells, CBC, coagulation profile (PT, aPTT, fibrinogen, D-dimer).
  4. Apply continuous electronic fetal and uterine monitoring.
  5. Position patient in the left lateral position; administer 100% oxygen via non-rebreather mask at 10 L/min.
  6. Insert an indwelling Foley catheter to monitor hourly renal perfusion (target > 30 mL/hr).
  7. Prepare the patient and operating room for an immediate emergency Cesarean section to preserve maternal and fetal life.

Comparison Matrix: Placenta Previa vs. Abruptio Placentae